amgen has launched two pivotal late-stage trials for maritide, an experimental weight loss drug aimed at entering the growing obesity treatment market, competing against other products from novo nordisk and eli lilly.

amgen is conducting late-stage trials for its weight loss drug maritide.

maritide is amgen's experimental weight loss injection currently in late-stage trials.

amgen's executive vice president of research and development, spoke about the trials.

novo nordisk produces existing weight loss drugs that maritide aims to compete against.

eli lilly also manufactures weight loss drugs that compete with maritide.